224 related articles for article (PubMed ID: 33148061)
1. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
4. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
[TBL] [Abstract][Full Text] [Related]
5. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
6. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
[TBL] [Abstract][Full Text] [Related]
7. Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
Aguiar CL; Pan N; Adams A; Barinstein L; Lehman TJ
Clin Rheumatol; 2015 Oct; 34(10):1821-4. PubMed ID: 25697878
[TBL] [Abstract][Full Text] [Related]
8. Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry.
Giancane G; Papa R; Vastert S; Bagnasco F; Swart JF; Quartier P; Antón J; Kamphuis S; Sanner H; Glerup M; De Benedetti F; Tsitsami E; Remesal A; Moreno E; De Inocencio J; Myrup C; Pallotti C; Koné-Paut I; Franck-Larsson K; Malmström H; Cederholm S; Pistorio A; Wulffraat N; Ruperto N;
J Rheumatol; 2022 Apr; 49(4):398-407. PubMed ID: 35105709
[TBL] [Abstract][Full Text] [Related]
9. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
10. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
Hedrich CM; Bruck N; Fiebig B; Gahr M
Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
17. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
Hinze CH; Holzinger D; Lainka E; Haas JP; Speth F; Kallinich T; Rieber N; Hufnagel M; Jansson AF; Hedrich C; Winowski H; Berger T; Foeldvari I; Ganser G; Hospach A; Huppertz HI; Mönkemöller K; Neudorf U; Weißbarth-Riedel E; Wittkowski H; Horneff G; Foell D;
Pediatr Rheumatol Online J; 2018 Jan; 16(1):7. PubMed ID: 29357887
[TBL] [Abstract][Full Text] [Related]
18. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
19. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]